BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 2569034)

  • 1. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
    Fekete M; Wittliff JL; Schally AV
    J Clin Lab Anal; 1989; 3(3):137-47. PubMed ID: 2569034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
    Fekete M; Redding TW; Comaru-Schally AM; Pontes JE; Connelly RW; Srkalovic G; Schally AV
    Prostate; 1989; 14(3):191-208. PubMed ID: 2471961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M; Zalatnai A; Schally AV
    Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane receptors for peptides in experimental and human pancreatic cancers.
    Fekete M; Zalatnai A; Comaru-Schally AM; Schally AV
    Pancreas; 1989; 4(5):521-8. PubMed ID: 2573055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
    Milovanovic SR; Radulovic S; Schally AV
    Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
    Srkalovic G; Wittliff JL; Schally AV
    Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
    Srkalovic G; Schally AV; Wittliff JL; Day TG; Jenison EL
    Int J Oncol; 1998 Mar; 12(3):489-98. PubMed ID: 9472084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
    J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Kahan Z
    Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
    Lee MT; Liebow C; Kamer AR; Schally AV
    Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N; Halmos G; Jungwirth A; Schally AV
    Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T; Pinski J; Radulovic S; Schally AV
    Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer.
    Reubi JC; Torhorst J
    Cancer; 1989 Sep; 64(6):1254-60. PubMed ID: 2569925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.